Your Health, We Care
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
FDA，2021.08
Lucius Version of Belzutifan: Dosage and Administration, Indications, Precaution···【more】
Release date：2025-12-04Recommended：8
